Kornimate/medical-research-clean huggingface dataset:
does recurrent pancreatic cancer really have similar outcome compared with primary metastatic pancreatic cancer?

Conditions: Pancreatic Cancer Metastatic

Summary: the recurrent pancreatic cancer (rec-pc) after radical surgery is sometimes eligible to clinical trial of chemotherapy for unresectable pancreatic cancer. however, the difference between rec-pc and primary metastatic pancreatic cancer (pm-pc) did not know well. thus, whether rec-pc and pm-pc should be included in the same category when conducting clinical trials evaluating chemotherapy remains controversial. the purpose of this study is to investigate the difference of overall survival (os) between rec-pc and pm-pc, and analyze their impact on prognosis.


Eligibility criteria:
inclusion criteria: * unresectable pancreatic cancer exclusion criteria: * patients expected to survive for less than three months
italian language validation of the eating disorder examination (ede) - child version

Conditions: Feeding and Eating Disorders of Childhood

Summary: although eating disorders often occur during or after puberty, it is likely that critical antecedent conditions can be established before adolescence. the eating disorder examination has been adapted for children and is described by bryant - waugh, cooper, taylor and lask (1996). the ede is considered the gold standard of measures of eating disorder psychopathology (wilson, 1993), and this adaptation, which allows its use with a younger age group, is a potentially important addition to the assessment of eating disorders in children. the latest version of ede, the l7th edition, has now surpassed its predecessors. the aim of the study is to evaluate the psychometric properties of the child vers ion ede (chede) translated into italian, in a sample of patients with eating disorder


Eligibility criteria:
inclusion criteria: * subjects meet a diagnosis of nutrition and eating disorder, specifically anorexia nervosa, bulimia nervosa, binge eating disorder, according to the criteria of the diagnostic and statistical manual of mental disorders dsm-5 * or (for control group) exclusion of a current or past eating disorder by performing pre-testing (kl subscales - sads) and bmi 17.5 * signed informed consent exclusion criteria: * schizophrenia or other psychotic disorders; * substance misuse in place * medical complications that have the potential to hinder interpretation of results ( e.g., a medical illness that induces weight loss) * presence of physical treatments (including medications) that have the potential to hinder interpretation of results (e.g., chemotherapy for cancer) * or (for control group) presence of a current or past eating disorder and/or ongoing eating disorder therapy
damage and renal clearance of glycocalyx in cardiac surgery

Conditions: Glycocalyx; Cardio-Renal Syndrome

Summary: the glycocalyx is a component of the vascular endothelium that currently plays a relevant role in the modified starling theory. the manipulation of the heart during cardiac surgery stimulates the release of the natriuretic atrial peptide, which causes endothelial wear in patients undergoing extracorporeal circulation. dilation of the atrium produces natriuretic atrial peptide, which reduces plasma volume by increasing renal excretion and vascular permeability. the atrial peptide degrades the surface of the coronary endothelium, causing loss of the side cam protein nucleus. this study investigates the relationship between clamping time in cardiac surgery and the clearance of endothelial inflammation markers.


Eligibility criteria:
inclusion criteria: * over 18 years of age * patients who underwent cardiac surgery for a single valve change or replacement exclusion criteria: * stage 3 renal failure patients * patients with a previous diagnosis of hematological malignancy * patients undergoing pulmonary valve change surgery. * patients undergoing bentall and bono surgery. * patients undergoing coronary artery bypass surgery

Keywords: renal clearance glycocalyx cardiac surgery
a study of abi-h2158 in healthy volunteers and patients with chronic hepatitis b

Conditions: Chronic Hepatitis B

Summary: this three-part, phase 1 protocol will be the first clinical study of abi-h2158. parts 1 and 2 will be a phase 1a, dose-ranging assessment of abi-h2158 in healthy adult volunteers. if the dose-related safety, tolerability, and pharmacokinetics (pk) of abi-h2158 in healthy volunteers are deemed satisfactory, then the study will advance to part 3, a phase 1b, dose-ranging assessment of abi-h2158 in non-cirrhotic, chb patients.


Eligibility criteria:
healthy volunteers: 1. male or female between 18 and 55 years old with a bmi of 18-34 kg/m2 with a minimum body weight of 45 kg 2. must be in good health and not have any health condition which could interfere with the absorption, distribution or elimination of study drug, or with the clinical and laboratory assessments in this study chronic hbv patients: key inclusion criteria: 1. male or female ≥ 18 and ≤ 65 years of age. 2. in good general health except for chronic hbv infection, documented by: 1. clinical history, physical exam and routine laboratory measurements without major or clinically significant findings 2. serologic profile consistent with chronic hbv infection • hbeag-positive at screening with hbv viral load ≥ 2× 105 iu/ml 3. liver evaluation demonstrating the absence of bridging fibrosis or cirrhosis key exclusion criteria: 1. history or evidence of decompensated liver disease at any time prior to screening 2. history or presence of any other clinically significant current medical conditions requiring ongoing pharmacological treatment. 3. previous treatment with any investigational hbv antiviral treatments within the last 6 months, or previous treatment at any time with an investigational hbv antiviral treatment of the same class (core protein targeted therapies). 4. previous treatment with a commercially approved hbv therapy within the last 6 months

Keywords: chb hbv hepatitis b hbeag positive
regenerative endodontic procedure of immature permanent teeth with apical periodontitis using prf

Conditions: Periapical Periodontitis; Tooth Diseases; Stomatognathic Diseases

Summary: this study evaluates the clinical effect of regenerative endodontic procedure using prf in immature permanent teeth with apical periodontitis. half of participants will receive the prf instead of blood clots in the regenerative endodontic procedure, while the other half will receive a blood clots in the regenerative endodontic procedure.

the conventional method of regenerative endodontic procedure using a blood clot as scaffold materials has shown successful results. however, it is very difficult to induce bleeding and place mineral trioxide aggregate over a blood clot. platelet-rich fibrin (prf), a second-generation platelet concentrate. prf is a matrix of autologous fibrin containing a large quantity of platelets, growth factors and leukocytes. prf preparation technique is very simple, inexpensive and doesn't require any chemical agents. the purpose of this study is to test the hypothesis that the use of prf in regenerative endodontic procedure of immature permanent teeth with apical periodontitis will accelerate periapical bone healing and stimulate the root maturation.

Eligibility criteria:
inclusion criteria: * between 6 and 18 years of age * provision of informed consent * cooperative in the dental chair * permanent immature teeth with apical periodontitis and incomplete root development exclusion criteria: * have a medical history that may complicate treatment * unlikely to be able to comply with the study procedures

Keywords: regenerative endodontic treatment platelet-rich fibrin immature permanent tooth apical periodontitis
multiparametric mri study of endogenous analgesia and prediction the efficacy of migraine pharmacological prevention

Conditions: Migraine

Summary: to delineate brain mechanisms that subserve ea in the healthy state and to identify alterations in mechanisms supporting ea in chronic pain and their therapeutic relevance. individuals with migraine will be examined between episodes in order to assess basal alterations in the efficiency of spatial and temporal filtering of noxious information. this population provides the unique opportunity to examine such processes without confounds arising from ongoing pain.

pain is a uniquely individual experience that is powerfully shaped by the action of descending control mechanisms. these systems may play crucial roles in the moment-to-moment tuning of the sensitivity, spatial, and temporal response characteristics of nociceptive processing mechanisms during both acute and pathological pain states. however, these systems remain poorly understood in human subjects. the proposed research will use psychophysics and multiparametric mri to (i) delineate the brain mechanisms that subserve and regulate endogenous analgesia (ea) in the healthy state and (ii) to identify alterations in mechanisms supporting ea in chronic pain and their therapeutic relevance. in both healthy subjects and chronic pain patients, ea will be probed using the dnic (diffuse noxious inhibitory controls) and offset analgesia paradigms. functional mri will examine activation of brainstem mechanisms important in ea, while both functional and structural connectivity analyses will assess the regulation of these brainstem mechanisms by cerebral cortical regions involved in attention and affect. one pathological painful condition, migraine, will be examined since it allows changes in ea associated with chronic pain to be investigated between episodes of pain. finally, ea and ea associated structural and functional parameters will be used to predict the efficacy of one compound, amitriptyline, to treat migraine in individual patients. taken together, the proposed research will provide substantial insights into basic mechanisms supporting and regulating ea and can provide a foundation for mechanism-based individualized choice of therapy that may benefit all chronic pain patients.

Eligibility criteria:
inclusion criteria: * patients diagnosed with migraine based on the international headache society (ihs) criteria 1 that have \>4 attacks/month, both with and without aura exclusion criteria: * patients receiving any migraine preventive treatment during last 3 months or prior treatment with amytriptiline * other chronic pain conditions * psychiatric, other neurological diseases, language barrier or cognitive dysfunction

Keywords: migraine pain cpm offset analgesia fmri
the natural history and treatment of acute hepatitis c virus (hcv) in hiv-positive individuals

Conditions: Acute Hepatitis C; HIV

Summary: the aim of the study is to investigate the epidemiology, natural history and treatment outcomes of acute hepatitis c (hcv) infection. given the current pattern of case reporting, the cohort will be largely made up of human immunodeficiency virus (hiv)-positive patients, but hiv-negative patients with acute hepatitis c (ahc) will also be enrolled to enable comparisons to be made as appropriate and possible.

in a multi-center, prospective, open cohort study, patients with documented acute hepatitis c infection will be followed prospectively over an initial time-period of 3 years after diagnosis of acute hepatitis c infection to investigate: 1. epidemiology * to describe the characteristics of patients who have acquired acute hcv infection, including examination of regional differences in modes of transmission, behavioural factors, concomitant sexually transmitted diseases, clinical presentation and associated laboratory test results. * characterization of the hcv strains circulating within the community using phylogenetic analysis 2. natural history * determination of the rate of spontaneous viral clearance, and the clinical, immunological, host genetic and viral factors associated with viral clearance * progression of liver disease after acute hepatitis c; including the use of non-invasive liver fibrosis markers to estimate rates of liver fibrosis progression 3. treatment strategies * describe the outcome of different treatment strategies for acute hcv infection, although it is acknowledged that there will be no random allocation of treatment strategies. * investigate factors associated with treatment response including time to initiation of therapy, duration of therapy, the use of ribavirin and genetic factors.

Eligibility criteria:
inclusion criteria: * documented current or past acute hepatitis c infection with detectable hcv-rna (pcr-assay) with an estimated duration of 52 weeks at diagnosis as defined below: * first hcv rna positive and * prior negative anti-hcv antibody or hcv rna test within 12 months or * rise of liver transaminases above 2.5 x upper limit of normal (uln) within the past 12 months with prior normal transaminases during the year before and * exclusion of other causes of acute hepatitis exclusion criteria: * acute liver disease other than hepatitis c * inability to provide written informed consent * younger than 18 years of age

Keywords: acute hepatitis c (hcv) human immunodeficiency virus (hiv)
efficacy study of p38 kinase inhibitor to treat patients with atherosclerosis

Conditions: Vascular Diseases

Summary: the purpose of the study is to determine whether a p38 kinase inhibitor reduces inflammation in atherosclerotic plaque


Eligibility criteria:
inclusion criteria: * history of documented atherosclerosis * ldl between 70 and 130 mg/dl * patients receiving stable low- to moderate-dose statin * bmi 18-37 kg/m² * must be able to swallow tablets * must be able to medically tolerate the procedures, contrast medium, and medications involved exclusion criteria: * statin intolerance * renal impairment (serum creatinine \> 1.5 mg/dl) * history of chronic viral hepatitis or other liver dysfunction * major infection requiring hospitalization or receipt of iv antibiotics due to an infection within 2 months prior to initiation of study treatment
evaluation of the gore conformable tag® for treatment of traumatic transection

Conditions: Thoracic Injuries

Summary: tag 08-02 is a prospective, multicenter, single-arm study to evaluate the use of the ctag device in traumatic transection of the descending thoracic aorta.


Eligibility criteria:
inclusion criteria: 1. traumatic transection of the dta that requires repair, determined by the treating physician 2. traumatic aortic transection location between, but does not include, the left subclavian artery and celiac artery 3. endovascular repair with the gore conformable tag® device performed less than or = to 14 days after aortic injury 4. age greater than or equal to 18 years 5. proximal and distal landing zone length greater than or equal to 2.0 cm. landing zones must be in native aorta. landing zone may include left subclavian artery, if necessary 6. all proximal and distal landing zone inner diameters are between 16-42 mm. diameter assessed by flow lumen and thrombus, if present; calcium excluded 7. subject capable of complying with study protocol requirements, including follow-up 8. informed consent form signed by subject or legal representative exclusion criteria: 1. differing proximal and distal neck diameters (aortic taper) outside the intended aortic diameter requirements (sizing guide) for a single endoprosthesis diameter and the inability to use devices of different diameters (in adherence to the sizing guide) to compensate for the taper 2. tortuous or stenotic iliac and/or femoral arteries and inability to use a conduit for vascular access 3. aneurysmal, dissected, heavily calcified, or heavily thrombosed landing zone(s) 4. infected aorta 5. subject has a systemic infection and may be at increased risk of endovascular graft infection 6. planned coverage of left carotid or celiac arteries with the ctag device 7. known degenerative connective tissue disease, e.g., marfan or ehler-danlos syndrome 8. treatment in another drug or medical device study within 1 year of study enrollment 9. known history of drug abuse 10. pregnant female 11. moribund patient not expected to live 24 hours with or without operation, determined by the treating physician 12. injury severity score of 75 13. subject has known sensitivities or allergies to the device materials

Keywords: aorta trauma transection
an extension of a long-term safety study of alks 9072 (also known as alks 9070)

Conditions: Schizophrenia

Summary: this is an extension of a previous study (alk9072-003ext). the purpose of this study is to continue to evaluate the long-term safety and durability of effect of alks 9072 in subjects with stable schizophrenia, and to allow subjects who are doing well on alks 9072 to continue treatment.


Eligibility criteria:
inclusion criteria: * completed the treatment period of study alk9072-003ext * continues to require chronic treatment with an antipsychotic medication * continues to reside in a stable living situation * continues to have an identified reliable informant exclusion criteria: * abnormal clinical laboratory value, vital sign, or electrocardiogram (ecg) finding during participation in study alk9072-003ext that was clinically relevant and related to study drug * missed more than 1 scheduled study visit during participation in the preceding study alk9072-003ext * has a significant or unstable medical condition that would preclude safe completion of the current study * subject is pregnant or breastfeeding * subject expects to be incarcerated, or has pending legal action which may impact compliance with study participation or procedures

Keywords: schizophrenia
digital weight bearing shape capture socket technology

Conditions: Amputation; Prosthesis User; Residual Limbs

Summary: the study will determine if symphonie aqua digital system, a new method of socket creation, in a weight-bearing environment, may produce more successful fitting and comfortability \& functional outcomes than traditional sockets (non-weight bearing scanning). additionally, the study will determine if a well-fitting socket will positively impact the overall health of amputee residual limb.

this study will compare the use of symphonie aqua digital system, which is a new way to create a socket for prosthetics, to the current method that is generally used to create sockets. the study will look at the differences in comfort and fit between the symphonie aqua digital system and the current standard of care (soc). the study will determine if symphonie aqua digital system, a new method of socket creation, in a weight-bearing environment, may produce more successful fitting and comfortability \& functional outcomes than traditional sockets (non-weight bearing scanning). additionally, the study will determine if a well-fitting socket will positively impact the overall health of amputee residual limb.

Eligibility criteria:
inclusion criteria: * ages 18 and above * unilateral trans-tibial amputees * ambulate at a k3 level or higher * at least 3 months post-amputation per physician discretion * trans-tibial limb length greater than 4.5 inches in length * able to follow directions and independently give informed consent * must be able to ambulate without assistance exclusion criteria: * age \< 18 years * conditions that prevent wearing a prosthetic socket * soc socket made with weight bearing system * cognitive deficits or mental health problems that would limit ability to consent and participate fully in the study protocol * women who are pregnant or who plan to become pregnant in the near future * weight \> 280 lbs
ultrasound guided corticosteroid injection at a1 pulley in comparison to percutaneous a1 pulley release as a treatment for idiopathic trigger finger

Conditions: US-guided Release of the A1 Pulley Responsible for Trigger Finger is Feasible With a 21-gauge Needle

Summary: objectives: to compare the efficacy of ultrasonography guided corticosteroid injection at a1 pulley and percutaneous a1 pulley release as a treatment for trigger finger. methods: 75 patients with idiopathic trigger finger were enrolled in our prospective study. patients with diabetes mellitus, previous history of open release for trigger finger, different inflammatory arthritis and multiple trigger fingers affections were excluded. group a 40 patients: underwent ultrasound guided methyl prednisolone acetate injection, between a1 pulley and tendons .group b 35 patients :underwent ultrasonography-guided percutaneous a1 pulley needle release .all patients were subjected to the following before and after intervention by 1 and 3 months , dash, trigger finger classification grade \& vas

trigger finger ( tf) is a pathologic problem of the finger leads to a painful tendon snap or click on flexion and extension, and/or locking of the metacarpophalangealor proximal interphalngeal joint (1) . entrapment of the affected tendon at the first annular (a1) pulley occurs because of a differencein the diameter of the flexor tendon and its sheath as a result of thickening of the sheath and or localized tendon thickening.(1) . most cases of trigger fingers are idiopathic and the incidence is around 28 cases per 100 000 population per year, or a lifetime risk of 2.6% in the general population and about 10% of patients are diabetics (1). women are usually more affected than men, usually in the fifth and sixth decades(2) it is more common in women than in men, usually in the dominant hand, and most often in the thumb or ring fingers followed . (2) the diagnosis of trigger finger is based mainly on the medical history and clinical examination. the most important characteristic clinical sign is the mechanical blocking of the finger when flexed with painful snapping extended. (3). management includes many options such as conservative treatment in the form of splinting, physical therapy, non-steroidal anti-inflammatory drugs, and local steroid injections, and surgical pulley release

Eligibility criteria:
inclusion criteria: * idiopathic trigger finger present for at least 3 months. exclusion criteria: * patients with diabetes mellitus, previous history of open release for trigger finger, different inflammatory arthritis and multiple trigger fingers affections.
a study of tirzepatide (ly3298176) in participants with type 2 diabetes on metformin with or without sulfonylurea (surpass-ap-combo)

Conditions: Type 2 Diabetes

Summary: the main reason for this study is to compare the study drug tirzepatide to insulin glargine in participants with type 2 diabetes on metformin with or without a sulfonylurea.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus * treated with stable metformin with or without a sulfonylurea (metformin ≥1000 milligrams/day; sulfonylurea should be at least half the maximum dose) for at least 2 months * are insulin-naive (except for the use of insulin for treatment of gestational diabetes or short-term use \[≤14 consecutive days\] for acute conditions) * hba1c ≥7.5% to ≤11.0% at screening * stable weight (±5%) ≥3 months, and agree to not initiate a diet and/or exercise program during the study with the intent of reducing body weight other than the lifestyle and dietary measures for diabetes treatment * body mass index (bmi) ≥23 kilograms per meter squared exclusion criteria: * type 1 diabetes mellitus * have history of chronic or acute pancreatitis * have history of proliferative diabetic retinopathy; or diabetic maculopathy; or non-proliferative diabetic retinopathy that requires acute treatment * have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months * have a history of ketoacidosis or hyperosmolar state/coma * have a known clinically significant gastric emptying abnormality, have undergone or plan to have during the course of the study, or chronically take drugs that directly affect gi motility * have acute myocardial infarction (mi), stroke or hospitalization due to congestive heart failure (chf) within 2 months * have family or personal history of medullary thyroid carcinoma (mtc) or multiple endocrine neoplasia syndrome type 2 (men-2) * have been treated with prescription drugs that promote weight loss or similar other body weight loss medications including over the counter (otc) within 3 months

Keywords: t2dm